BrightPath Biotherapeutics Co., Ltd.
Save
4.65B
Market cap
–
Current P/E
–
Forward P/E
About
Health care
Sector
Biotechnology
Industry
BrightPath Biotherapeutics Co., Ltd. develops cancer immunotherapy drugs. The company is developing GRN-1201 that is in Phase II clinical study for the treatment of non-small cell lung cancer, as well as in Phase I clinical study to treat melanoma. It also develops BP1101, a neoantigen vaccine; BP1209, a platform of personalized neoantigen cancer vaccines; and BP1401, an agonist for toll-like receptor 9.
Similar securities
Based on sector and market capitalization
Report issue